Mazdutide
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Innovent · Phase 1/2 · Active, not recruiting · Enrollment 98
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| IBI362 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Tirzepatide | Obesity or overweight | n/r | n/r | n/r | n/r |